MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1572-0241.2008.01860.x

Медицинская библиотека · The American journal of gastroenterology · 2008

Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial.

Fukuda Yoshihiro, Takazoe Masakazu, Sugita Akira, Kosaka Tadashi, Kinjo Fukunori, Otani Yoshimasa, Fujii Hisao, Koganei Kazutaka, Makiyama Kazuya, Nakamura Toshio, Suda Takeyasu, Yamamoto Shojiro, Ashida Toshifumi, Majima Akira, Morita Norikazu, Murakami Kazunari, Oshitani Nobuhide, Takahama Kazuya, Tochihara Masahiro, Tsujikawa Tomoyuki, Watanabe Makoto

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

Anal fistulas are common in individuals with Crohn's disease (CD). We sought to evaluate the efficacy of oral spherical adsorptive carbon (AST-120) (Kremezin; Kureha Corporation, Tokyo, Japan) for the treatment of intractable anal fistulas in patients with CD.

METHODS

In this multicenter, randomized, double-blind, placebo-controlled trial, patients with CD and at least one active anal fistula under treatment were assigned to receive either AST-120 or placebo for 8 wk. Improvement was defined as a reduction of 50% or more from baseline in the number of draining fistulas observed at both 4 and 8 wk. Remission was defined by closure of all draining fistulas at both 4 and 8 wk. The Perianal Disease Activity Index (PDAI) and Crohn's Disease Activity Index (CDAI) were also assessed.

RESULTS

In total, 62 patients were randomized, of whom 57 received AST-120 (N = 27) or placebo (N = 30). The improvement rate in the AST-120 group (37.0%) was significantly greater than that in the placebo group (10.0%) (P= 0.025). The corresponding remission rates were 29.6% and 6.7%, respectively (P= 0.035). PDAI significantly improved at both 4 and 8 wk with AST-120, compared to placebo (P= 0.004 and P= 0.005, respectively). CDAI was also significantly improved at both 4 and 8 wk in the AST-120 group, compared to the placebo group (P= 0.007 and P= 0.001, respectively). AST-120 treatment was well tolerated and no life-threatening adverse events were observed.

CONCLUSION

AST-120 is useful for the control of intractable anal fistulas in CD patients.

Для цитирования: Fukuda Yoshihiro, Takazoe Masakazu, Sugita Akira, Kosaka Tadashi, Kinjo Fukunori, Otani Yoshimasa, Fujii Hisao, Koganei Kazutaka, Makiyama Kazuya, Nakamura Toshio, Suda Takeyasu, Yamamoto Shojiro, Ashida Toshifumi, Majima Akira, Morita Norikazu, Murakami Kazunari, Oshitani Nobuhide, Takahama Kazuya, Tochihara Masahiro, Tsujikawa Tomoyuki, Watanabe Makoto. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial.. The American journal of gastroenterology. 2008. DOI: 10.1111/j.1572-0241.2008.01860.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.